HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships.
Levinson. Pauline P; Choi. Robert Y RY; Cole. Amy L AL; Hirbod. Taha T; Rhedin. Samuel S; Payne. Barbara B; Guthrie. Brandon L BL; Bosire. Rose R; Cole. Alexander M AM; Farquhar. Carey C; Broliden. Kristina K
Key Findings
- LL‑37 and HNP1‑3 are present in cervicovaginal secretions of women regardless of HIV status
- Higher male partner viral load is linked to increased LL‑37 and HNP1‑3 levels
- The secretions can neutralize HIV, and this activity depends on the cationic peptides
- Removing the peptides eliminates neutralizing activity; adding recombinant LL‑37 restores it
Practical Outcomes
- Boosting LL‑37 (e.g., via vitamin D or other safe methods) might enhance natural HIV protection, but the inflammatory side‑effects mean any approach should be tested carefully. Currently there’s no specific dosage or protocol, so biohackers should view this as a promising target rather than a ready‑to‑use hack.
Summary
The study shows that the natural peptide LL‑37 (and related HNP1‑3) in vaginal fluids can block HIV, and higher levels are seen when a partner has a high viral load. Removing these peptides stops the protective effect, while adding them back restores it, but they can also cause inflammation.
Abstract
HIV exposed seronegative (HESN) women represent the population most in need of a prophylactic antiviral strategy. Mucosal cationic polypeptides can potentially be regulated for this purpose and we here aimed to determine their endogenous expression and HIV neutralizing activity in genital secretions of women at risk of HIV infection. Cervicovaginal secretions (CVS) of Kenyan women in HIV-serodiscordant relationships (HESN, n = 164; HIV seropositive, n = 60) and low-risk controls (n = 72) were assessed for the cationic polypeptides HNP1-3, LL-37 and SLPI by ELISA and for HIV neutralizing activity by a PBMC-based assay using an HIV primary isolate. Median levels of HNP1-3 and LL-37 in CVS were similar across study groups. Neither HSV-2 serostatus, nor presence of bacterial vaginosis, correlated with levels of HNP1-3 or LL-37 in the HESN women. However, an association with their partner's viral load was observed. High viral load (>10,000 HIV RNA copies/ml plasma) correlated with higher levels of HNP1-3 and LL-37 (p = 0.04 and 0.03, respectively). SLPI was most abundant in the low-risk group and did not correlate with male partner's viral load in the HESN women. HIV neutralizing activity was found in CVS of all study groups. In experimental studies, selective depletion of cationic polypeptides from CVS rendered the remaining CVS fraction non-neutralizing, whereas the cationic polypeptide fraction retained the activity. Furthermore, recombinant HNP1-3 and LL-37 could induce neutralizing activity when added to CVS lacking intrinsic activity. These findings show that CVS from HESN, low-risk, and HIV seropositive women contain HIV neutralizing activity. Although several innate immune proteins, including HNP1-3 and LL-37, contribute to this activity these molecules can also have inflammatory properties. This balance is influenced by hormonal and environmental factors and in the present HIV serodiscordant couple cohort study we show that a partner's viral load is associated with levels of such molecules.
Study Information
pubmed
2012
2012-02-28T00:00:00.000Z
10.1371/journal.pone.0031996
67
31